News & Updates
Showing Pharmacy articles
Showing

Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

Long-term statin users at risk of colon cancer
Use of statins does not appear to be chemopreventive against colorectal cancer (CRC), and no significant association exists between total cholesterol level and CRC risk, a study has found. In addition, long-term statin use may increase the risk of colon cancer.






